register

News & Trends - Pharmaceuticals

Aussie Kazia licenses commercialisation rights for oncology drug to China’s Simcere

Health Industry Hub | March 31, 2021 |

Pharma News: Kazia Therapeutics, an oncology-focused drug development company in Australia, entered into a licensing agreement with Simcere Pharmaceutical Group to develop and commercialise Kazia’s investigational new drug, paxalisib, in Greater China.

Simcere will assume responsibility for the development, registration and commercialisation of paxalisib in Greater China. Kazia retains rights to the development and commercialisation of paxalisib in all other territories and will continue to drive forward the GBM AGILE pivotal study as planned, including in China.

Kazia CEO, Dr James Garner, commented “China is one of the world’s largest pharmaceutical markets, with specific requirements and opportunities for innovative oncology products. We are delighted to partner with Simcere to secure the commercial success of paxalisib in this critical territory. Simcere’s track record of success is unrivalled, and they bring to paxalisib first-class capabilities in clinical development, regulatory affairs, and commercialisation. We look forward to working closely with our new partners to make paxalisib available for Chinese patients as swiftly as possible.”

Digital & Innovation - Health Industry Hub Digital Series

Dr Renhong Tang, Senior Vice President at Simcere, added “we are tremendously excited by the potential for paxalisib to make a difference in this very challenging disease. The need for new therapies in brain cancer is significant in China, and we share Kazia’s commitment to bringing forward new treatment options for patients.”

Under the terms of the agreement, Kazia will receive an upfront payment of US$ 11 million (~AU$ 14.2 million). Kazia will also receive contingent milestone payments of up to US$ 281 million (~AU$ 362 million) for glioblastoma, with further milestones payable for indications beyond glioblastoma. Simcere will additionally pay to Kazia mid-teen percentage royalties on commercial sales.

Paxalisib is currently the subject of six additional studies in other forms of brain cancer beyond glioblastoma.

You may also like TGA approval positions Australia at the forefront of innovation in allergy and anaphylaxis management


News & Trends - MedTech & Diagnostics

Medtronic partners with local researchers in stroke trial

Medtronic partners with local researchers in stroke trial

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: Endovascular thrombectomy has been shown to be more effective in reducing disability than medical therapy alone […]

More


News & Trends - Pharmaceuticals

Health Ministers reflect on the reforms and complexities facing the healthcare system

Health Ministers reflect on the reforms and complexities facing the healthcare system

Health Industry Hub | March 1, 2024 |

Pharma News: Mark Butler MP, Federal Minister for Health, and Senator Anne Ruston, Shadow Minister for Health, reflected on the […]

More


News & Trends - Pharmaceuticals

Gilead seeks funding of CAR T-cell therapy in follicular lymphoma

Gilead seeks funding of CAR T-cell therapy in follicular lymphoma

Health Industry Hub | March 1, 2024 |

Pharma News: Gilead has applied to the Medical Services Advisory Committee (MSAC) for funding of its cutting-edge CAR T-cell therapy, […]

More


News & Trends - MedTech & Diagnostics

Should private insurers face scrutiny for soaring profits while patients foot the bill? MTAA, Private Healthcare Australia

Should private health insurers face scrutiny for soaring profits while patients foot the bill?

Health Industry Hub | March 1, 2024 |

MedTech & Diagnostics News: In a clash of interests, the Medical Technology Association of Australia (MTAA) has once again urged […]

More


This content is copyright protected. Please subscribe to gain access.